Literature DB >> 16477537

Adipose tissue and circulating endothelial cell specific molecule-1 in human obesity.

J Janke1, S Engeli, K Gorzelniak, M Feldpausch, U Heintze, J Böhnke, M Wellner, F Herse, P Lassalle, F C Luft, A M Sharma.   

Abstract

Adipocytes produce the endothelial-cell specific molecule-1 (ESM-1), which inhibits leukocyte adhesion and migration through the endothelium. This study investigates ESM-1 expression and regulation in human adipose tissue. Subcutaneous abdominal adipose tissue was obtained from seventy postmenopausal women. Fourteen women subsequently underwent non-pharmacological weight reduction. In vitro experiments were performed on adipocytes isolated from human mammary adipose tissue. We determined gene expression by TaqMan RT-PCR and measured ESM-1 levels in serum and cell culture medium by ELISA. Mature adipocytes produced ESM-1. ESM-1 gene expression was higher in adipocytes than in preadipocytes. Cortisol inhibited ESM-1 gene expression in preadipocytes. Insulin and cortisol inhibited adipocyte ESM-1 production in adipocytes. This inhibitory effect of insulin was attenuated by insulin resistance, as ESM-1 gene expression in subcutaneous adipose tissue was increased in obese, hyperinsulinemic women. In contrast, ESM-1 serum levels were reduced in obese women and inversely correlated to C-reactive protein levels. Five percent weight loss did not markedly change gene expression. Circulating ESM-1 levels increased significantly, albeit modestly. ESM-1 is actively produced by adipocytes. However, since ESM-1 adipocyte gene expression and circulating plasma levels are not correlated, other sources of ESM-1 may be more important. Circulating ESM-1 levels are reduced in the overweight and obese, consistent with the notion that ESM-1 may play some role in obesity-associated vascular disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16477537     DOI: 10.1055/s-2006-924973

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  16 in total

1.  Changes in Proteomic Profiles are Related to Changes in BMI and Fat Distribution During 10 Years of Aging.

Authors:  Lars Lind; Sylwia Figarska; Johan Sundström; Tove Fall; Johan Ärnlöv; Erik Ingelsson
Journal:  Obesity (Silver Spring)       Date:  2019-12-05       Impact factor: 5.002

2.  Can the Serum Endocan Level Be Used as a Biomarker to Predict Subclinical Atherosclerosis in Patients with Prediabetes?

Authors:  Yucel Arman; Adem Atici; Ozgur Altun; Remzi Sarikaya; Sengül Aydin Yoldemir; Murat Akarsu; Orkide Kutlu; Guzin Zeren Ozturk; Pinar Demir; Mustafa Ozcan; Recep Yilmaz Bayraktarli; Tufan Tukek
Journal:  Arq Bras Cardiol       Date:  2022-08-05       Impact factor: 2.667

3.  A closer look at the role of urotensin II in the metabolic syndrome.

Authors:  Pierre-Olivier Barrette; Adel Giaid Schwertani
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-28       Impact factor: 5.555

4.  The Relationship between Serum Endocan Levels and Depression in Alzheimer's Disease.

Authors:  Kyung Hee Yoon; So Yeon Kim; Yoo Sun Moon; Daeyoung Roh; Sang Kyu Lee; Do Hoon Kim
Journal:  Dis Markers       Date:  2016-01-26       Impact factor: 3.434

Review 5.  Endocan and the respiratory system: a review.

Authors:  Maria Kechagia; Ioannis Papassotiriou; Konstantinos I Gourgoulianis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-12-12

6.  Endocan as a prognostic biomarker of triple-negative breast cancer.

Authors:  Atsunobu Sagara; Katsuhide Igarashi; Maky Otsuka; Akihiro Kodama; Mutsumi Yamashita; Rei Sugiura; Takeshi Karasawa; Kazuhiko Arakawa; Michiko Narita; Naoko Kuzumaki; Minoru Narita; Yoshinori Kato
Journal:  Breast Cancer Res Treat       Date:  2016-11-25       Impact factor: 4.872

7.  Identification of novel biomarkers to monitor β-cell function and enable early detection of type 2 diabetes risk.

Authors:  Kirstine J Belongie; Ele Ferrannini; Kjell Johnson; Patricia Andrade-Gordon; Michael K Hansen; John R Petrie
Journal:  PLoS One       Date:  2017-08-28       Impact factor: 3.240

8.  The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients - preliminary report.

Authors:  Agnieszka Owczarczyk-Saczonek; Marek Drozdowski; Agata Maciejewska-Radomska; Dariusz Choszcz; Waldemar Placek
Journal:  Postepy Dermatol Alergol       Date:  2018-02-20       Impact factor: 1.837

Review 9.  Proteoglycans in Obesity-Associated Metabolic Dysfunction and Meta-Inflammation.

Authors:  Ariane R Pessentheiner; G Michelle Ducasa; Philip L S M Gordts
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

10.  Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan.

Authors:  Maryse Delehedde; Lucie Devenyns; Claude-Alain Maurage; Romain R Vivès
Journal:  Int J Cell Biol       Date:  2013-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.